Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma

Table 2 Univariate analysis of disease-free and overall patient survivals with hepatocellular carcinoma

Clinicopathological Parameters	Median Disease-free survival	P value	Median Overall survival	P value
Age
< 65 years	237	0.349	1267	0.673
≥ 65 years	594		1234
Gender
Male	673	0.079	1283	0.568
Female	283		1092
Virus
HBV	237	0.178	1211	0.968
HCV	325		1283
None	847		1234
Miran Criteria
In	847	0.061	1940	0.006
Out	256		572
AFP
High (n = 20)	237	0.004	573	0.042
> 10 ng/mL
Low (n = 20)	847		1818
≤ 10 ng/mL
FGF19T
High (n = 20)	283	0.021	628	0.018
Low (n = 20)	413		1758
Tumor size
< 5 cm	717	0.171	1428	0.028
≥ 5 cm	256		498
Histologic type of tumor
Well differentiated	673	0.813	1428	0.712
Moderately differentiated	323		1234
Poorly differentiated	594		1092
Formation of fibrous capsule
Present	413	-------	1267	-------
Absent	64		64
Capsular infiltration
Present	403	0.853	1234	0.725
Absent	64		64
Septal formation
Present	325	0.872	1230	0.777
Absent	413		1283
Serosal invasion
Present	104	-------	172	-------
Absent	413		1267
Portal invasion
Present	283		825	0.105
Absent	881		1940
Hepatic vein invasion
Present	256	0.215	573	0.150
Absent	597		1428
Intrahepatic metastasis
Present	283	0.020	628	0.020
Absent	881		1983
Bile duct invasion
Present	403	-------	1267	-------
Absent	413		573
Lymph node metastasis
Present	256	-------	347	-------
Absent	413		1267
Pathological stage
II	1373	-------	2085	0.060
III	594		1234
IV	237		572

ISSN: 1471-2407